Akosua Mireku

Paolo Morgese, vice president of European public affairs at the Alliance for Regenerative Medicine, discusses the barriers affecting access to gene therapies.

At the Swiss Biotech Day conference, experts discussed how the development of antibody drug conjugates (ADCs) may evolve in the near future.

At the Swiss Biotech Day Conference, key opinion leaders discussed ways to reduce disparities caused by reduced regulatory capacities.

At the Swiss Biotech Day conference, key opinion leaders discussed trends in pharmaceutical partnerships. Share this article Copy Link

At the Swiss Biotech Day conference, panelists at an investment talk discussed the current state of the Swiss investment landscape.

Experts hold scalability challenges and high costs accountable for market failures within the cell and gene therapy landscape. Share this article Copy Link

US regulators have added more Chinese biotech companies to the list of firms posing national security risks to the US.

US lawmakers have added more Chinese biotech and medtech companies to the list of firms posing national security risks that they are seeking to prevent doing business with the US.

At the London Biotechnology Show, Microsoft’s senior director of life sciences discussed the ethical use of GenAI.

At the London Biotechnology Show, Microsoft's senior director of life sciences discussed the ethical use of GenAI.